Regulated trials

Regulated trials

A regulated trial is a clinical trial that is subject to the oversight of national or international regulatory authorities. These include agencies such as the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), Health Canada, and others. Regulated trials typically involve investigational drugs, biologics, medical devices, or advanced therapy medicinal products (ATMPs), and must comply with rigorous standards to ensure patient safety, ethical conduct, and data integrity.

Key Regulatory Bodies and Guidelines

Regulatory requirements vary by region, but all are grounded in ethical principles and scientific rigor. The following table outlines key agencies and their guiding regulations:

Regulatory Agency	Jurisdiction	Key Guidelines
FDA (Food and Drug Administration)	USA	21 CFR 312 (Drugs), 21 CFR 812 (Devices)
EMA (European Medicines Agency)	European Union	Clinical Trials Regulation (EU CTR No 536/2014)
MHRA (Medicines and Healthcare products Regulatory Agency)	UK	UK Clinical Trials Regulations
Health Canada	Canada	Food and Drugs Act, Division 5
TGA (Therapeutic Goods Administration)	Australia	Australian Clinical Trial Handbook
ICH-GCP (International Council for Harmonisation – Good Clinical Practice)	Global	ICH E6 (GCP)

These guidelines ensure that regulated trials meet internationally accepted standards of scientific validity, ethical conduct, and operational quality.

Types of Regulated Trials

Drug trials are conducted to evaluate investigational new drugs (INDs) or new indications for approved drugs. These trials must be preceded by preclinical studies and follow a structured development path through clinical phases. Common examples include oncology drug trials and vaccine development.

Biologic trials focus on biological products such as monoclonal antibodies, gene therapies, and vaccines. These require a Biologics License Application (BLA) for approval and are often subject to stricter long-term safety monitoring. Examples include mRNA vaccines and CAR-T therapies.

Medical device trials are used to evaluate diagnostic or therapeutic devices like pacemakers, surgical robots, or wearable health monitors. In the U.S., they often require an Investigational Device Exemption (IDE) prior to human testing.

Advanced Therapy Medicinal Products (ATMPs) include cell therapies, gene therapies, and tissue-engineered products. Due to their complexity and potential for long-term effects, ATMP trials are heavily regulated and monitored.

Phases of Regulated Trials

Drug and biologic trials typically follow four clinical phases:

Phase	Objective	Sample Size	Key Features
Phase 1	Safety & Dosage	20–100 participants	First-in-human studies, dose escalation, pharmacokinetics
Phase 2	Efficacy & Safety	100–500 patients	Early signs of efficacy, optimal dosing
Phase 3	Confirmatory Efficacy	1,000+ patients	Large-scale, multicenter randomized controlled trials
Phase 4	Post-Marketing Surveillance	Real-world patients	Long-term safety, rare adverse events

Medical device trials may follow different stages (e.g., Pilot, Pivotal, and Post-Market Surveillance), aligned with device-specific regulatory frameworks.

Key Regulatory Requirements

Ethical approval and informed consent are mandatory for all regulated trials. Institutional Review Board (IRB) or Ethics Committee (EC) approval must be obtained before trial initiation, and participants must sign an informed consent form (ICF) outlining risks, benefits, and rights.

Trial registration is required in public registries such as ClinicalTrials.gov (USA) or EudraCT (EU), to promote transparency and accountability.

Good Clinical Practice (GCP) compliance ensures that trials follow international standards for data quality, participant protection, monitoring, and documentation. ICH-GCP (E6) is the most widely recognized global framework.

Adverse event and safety reporting is critical. Serious Adverse Events (SAEs) must be promptly reported to regulatory bodies. Many trials have a Data Safety Monitoring Board (DSMB) responsible for ongoing safety oversight.

Regulatory submissions are needed at various stages. Trials often begin with an IND or IDE application and culminate in a New Drug Application (NDA), Biologics License Application (BLA), or Premarket Approval (PMA) for devices.

Post-marketing surveillance (Phase 4) assesses real-world safety and effectiveness. Regulators may issue warnings, recall products, or restrict indications based on emerging data.

Challenges in Regulated Trials

Regulated trials are often complex and resource-intensive. Regulatory requirements vary across countries, requiring harmonization for global studies. Phase 3 trials are particularly expensive and may take years to complete. Ethical dilemmas may arise when balancing innovation with participant safety.

Recruitment and retention are persistent challenges, especially when trials require large, diverse populations. Ensuring representative enrollment and long-term follow-up can be difficult in real-world settings.

Examples of Major Regulated Trials

• Pfizer-BioNTech COVID-19 Vaccine Trial: Conducted under the FDA’s Emergency Use Authorization (EUA) pathway.
• CAR-T Cell Therapy Trials: Evaluated under the FDA’s Regenerative Medicine Advanced Therapy (RMAT) designation.
• Apple Heart Study: A wearable device trial that used decentralized digital trial methods for regulatory engagement.

Conclusion

Regulated clinical trials are essential for ensuring the safety, efficacy, and quality of medical interventions. They play a critical role in advancing evidence-based healthcare while protecting public health. Although these trials are complex, costly, and time-consuming, they are foundational to drug and device development and remain the gold standard for regulatory approval.

---

Bibliography

1. Schulz KF, Grimes DA. Generation of allocation sequences in randomised trials: chance, not choice. The Lancet. 2002;359(9305):515–519.
2. Altman DG, Bland JM. Statistics notes: how to randomise. BMJ. 1999;319(7211):703–704.
3. Moher D, Hopewell S, Schulz KF, et al. CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. BMJ. 2010;340:c869.
4. Piantadosi S. Clinical Trials: A Methodologic Perspective. 3rd ed. Wiley; 2017. Chapter 7: Randomization methods and implementation.
5. Higgins JPT, Thomas J, Chandler J, et al. (editors). Cochrane Handbook for Systematic Reviews of Interventions, version 6.3 (updated February 2022). Cochrane; 2022. Chapter 8: Random sequence generation and allocation concealment.

---

Adapted for educational use. Please cite relevant trial methodology sources when using this material in research or teaching.